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Abstract The mammary epithelium is a highly heterogenous
and dynamic tissue that includes a range of cell types with
varying levels of proliferative capacity and differentiation po-
tential, from stem to committed progenitor and mature cells.
Generation of mature cells through expansion and specifica-
tion of immature precursors is driven by hormonal and local
stimuli. Intriguingly, although circulating hormones can be
directly sensed only by a subset of mammary cells, they also
regulate the behaviour of cells lacking their cognate receptors
through paracrine mechanisms. Thus, mapping the hormonal
signalling network on to the emerging mammary cell hierar-
chy appears to be a difficult task. Nevertheless, a first step
towards a better understanding is the characterization of the
hormone receptor expression pattern across individual cell
types in the mammary epithelium. Here we review the most
relevant findings on the cellular distribution of hormone re-
ceptors in the mammary gland, taking into account differences
between mice and humans, the methods employed to assess
receptor expression as well as the variety of approaches used
to resolve the mammary cell heterogeneity.
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Abbreviations
ALDH Aldehyde dehydrogenase
AR Androgen receptor
CFC Colony-forming cell
ER Oestrogen receptor
FACS Fluorescence-activated cell sorting
MaSC Mammary stem cell
MRU Mammary repopulating unit
PI-MECs Parity-identified mammary epithelial cells
PR Progesterone receptor
Prlr Prolactin receptor
Introduction
Systemic hormones are crucial regulators of mammary gland
development and function throughout reproductive life [1, 2].
Oestrogen and growth hormone drive ductal elongation at the
onset of puberty, whereas cyclic fluctuations of oestrogen and
progesterone sustain subsequent remodelling of the ductal net-
work [1, 3]. During pregnancy, progesterone and prolactin
induce the formation of alveolar structures capable of milk
production [1, 4].
Although the morphogenetic responses elicited by repro-
ductive hormones in the mammary gland have been exten-
sively studied for decades, the precise mechanisms of hor-
mone action and the underlying cell dynamics have only re-
cently emerged. It is now well established that in the mamma-
ry epithelium a subset of cells can directly sense systemic
hormones and convert them into local signals to influence
the behaviour of neighbouring cells [2, 5]. However, the dis-
covery of a hierarchical cell organization in the mammary
epithelium has further complicated this scenario, prompting
the investigation of the hormone receptor status across various
mammary cell types with distinctive proliferative capacities
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and differentiation potentials. Mapping hormone receptor ex-
pression along the mammary cell hierarchy is crucial for un-
derstanding how hormonal signalling coordinates the recruit-
ment and lineage commitment of stem/progenitor cells in sup-
port of normal mammary tissue homeostasis and remodelling.
Moreover, deciphering this puzzle may reveal how disruption
of hormone receptor patterning can contribute to development
and maintenance of breast cancer.
This review summarizes our current knowledge regarding
the cellular distribution of hormone receptors in the mouse
and human mammary epithelium, with a primary focus on
the expression pattern of the receptors for the ovarian steroid
hormones oestrogen and progesterone (ER and PR, respec-
tively). Furthermore, given the presence of heterogeneity in
the hormone receptor-positive population, we will also discuss
recent studies, which underscore that not all the hormone
receptor-positive cells are equivalent with respect to their fate
and function in the mammary epithelium.
Cell Heterogeneity and Hormone Receptors
in the Mammary Epithelium: Biology
and Methodology at a Glance
The mammary epithelium consists of an outer layer of basal
cells, most of which are contractile myoepithelial cells, and an
inner layer of luminal cells [6]. Luminal cells include ductal
and alveolar epithelial cells, which line the ducts and form the
alveoli that develop during pregnancy, respectively. Luminal
alveolar cells primarily function as milk-secreting cells
throughout lactation [6]. These cell lineages derive from un-
differentiated precursors, which expand and progress along
specific differentiation pathways in response to hormonal
and local stimuli [6]. Of course, the different stages through
which the mammary epithelium develops have different hor-
monal contexts; these ultimately determine the extent of pro-
gression towards terminal differentiation along any lineage
pathway as well as the degree of expansion in cell number
within any lineage required to fulfil the functional purpose of
the tissue.
Over the past recent years, our understanding of the mam-
mary hierarchical cell organization has significantly increased.
Combining fluorescence-activated cell sorting (FACS) and a
variety of functional assays, epithelial cell populations with
features of stem, progenitors and mature cells have been iden-
tified and characterized both in the mouse and human mam-
mary gland [7–9]. In spite of some differences in the panels of
cell surface markers between species, it seems that analogous
subpopulations have highly conserved gene expression pro-
files and functions [7–9].
Based on this cell separation / functional analysis approach,
stem cells have been localised to the basal cell layer, whereas
progenitors have been largely found in the luminal
compartment [7–9]. Mouse mammary stem cells (MaSCs)
have also been referred as mammary repopulating units
(MRUs), due to their ability to regenerate the complete mam-
mary epithelium when injected into a mammary fat pad
cleared of the endogenous epithelium [10, 11]. Similarly, hu-
man MRUs can be identified upon transplantation under the
renal capsule of immunodeficient mice or into Bhumanized^
mouse mammary fat pads [10, 11]. Additionally, MaSCs are
recognized for their ability to resist from anoikis in vitro in
non-adherent cultures and generate floating colonies, known
as mammospheres [11]. In contrast, by virtue of their high
proliferative potential but limited repopulating capacity, pro-
genitor cells are detectable in vitro by colony-forming cell
(CFC) assays [10]. Terminally differentiated cells do not trans-
plant in vivo or form colonies in vitro and appear unable to
proliferate, at least in the current tested conditions.
The use of dissociated mammary epithelial cells, even
when freshly isolated, can be an important caveat to MRU
and CFC assays in determining cell regenerative and differen-
tiation potential. In fact, it is now emerging that the plasticity
of mammary cells, observed after tissue disaggregation and
loss of the original homeostatic context, may not reflect be-
haviour of cells in intact glands. Unlike such assays, cell lin-
eage tracing experiments allow to track stem and progenitor
cells and their progeny in situ. Yet lineage tracing has
highlighted the possible existence of bipotent stem cells as
well as long-lived unipotent cells and a variety of precursors
that are recruited during morphogenesis and homeostasis in
the mammary gland [7, 12–16]. However, discrepancies
among results from separate studies indicate that caution is
necessary during the design and analysis of transgenic reporter
models for lineage tracing.
In contrast to the doubt that still remains over how many
‘stem-like’ cell populations exist and their location in the mam-
mary epithelium, cells which express the intracellular receptors
for the steroid hormones oestrogen and progesterone have been
well-studied in situ. Multiple and functionally distinct isoforms
of the oestrogen receptor (ER) and the progesterone receptor
(PR) are found in mammary cells [17] and, as a result of their
dimerization, the functional variety of these receptors is likely
to be wider, including various ER homo- and hetero-dimers as
well as various PR homo- and hetero-dimers.
There are two major ER isoforms, ERα and ERβ. Both in
rodents and in humans ERα is confined to the luminal layer of
the mammary epithelium [18–20], whereas ERβ has a wide-
spread distribution [21, 22]. The two main PR forms, PRA
and PRB, largely co-localize and are both restricted to the
luminal epithelium in human breast [23]. However, differen-
tial expression of these two isoforms has been observed at
distinct stages of development in the mouse mammary gland,
with the presence of only PRA in virgin animals and the pref-
erential expression of PRB during pregnancy [24]. As most of
the studies reviewed here are related to ERα and do not
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distinguish the two PR forms, hereafter ER will refer to ERα
while PR will not refer exclusively to PRA or PRB, unless
otherwise specified.
In situ analysis of ER and PR expression has demonstrated
a precise spatial distribution of the cells that can be directly
targeted by steroid hormones in the mammary gland [18–20,
23, 24], but provided limited information about the functional
properties of these cells. In order to define the position of
hormone sensing cells along the mammary differentiation hi-
erarchy, mammary biologists have prospectively isolated dis-
crete putative stem, progenitor and mature cells by flow cy-
tometry and analyzed them for the expression of steroid hor-
mone receptors [25–35] (Tables 1 and 2). Alternatively, they
have employed cell surface markers to enrich for steroid hor-
mone receptor-positive or negative cells and assessed their
growth and differentiation potential using in vitro and
in vivo assays [29–32] (Fig. 1). Gene expression analysis on
these isolated cell fractions has revealed the average ER and
PR transcript levels for each population, whereas analysis of
ER and PR staining in single sorted cells has provided mainly
qualitative information on the heterogeneity of the hormone
receptor status within distinct populations. Importantly, the
intrinsic sensitivity of the method employed to detect ER
and PR expression should be considered while comparing
data from independent studies. As well, the existence ofmech-
anisms of post-transcriptional regulation of ER and PR ex-
pression [36, 37] may account for discrepancies between
mRNA and protein levels. Below, we discuss in detail the
variety of strategies used to assess hormone receptor expres-
sion across discrete mammary subpopulations in mice and
humans, as well as the resulting findings and what they tell
us about the role(s) of hormone receptor expressing cells in the
mammary epithelium.
Table 1 Expression of ER and PR in distinct normal human mammary epithelial subpopulations
Markers Phenotype Description ER
expression
PR
expression
Detection method
CD10
CD24
CD44 [33]
CD10− CD24− CD44+ Stem/Progenitor cells – +/− Semi-quantitative RT-PCRa
EpCAM
CD49f
CD133
MUC1
CD10
THY1 [28]
EpCAM+ CD49f − Mature Luminal Cells ++ ++ Long SAGEb and Affimetrix
analysis, qRT-PCRcMUC1+CD133+
CD10− THY1−
EpCAM+ CD49f+ Bipotent progenitors + ++
MUC1− CD133−
CD10+ THY1+
EpCAM+ CD49f+ Luminal-restricted progenitors +++ +
MUC1+ CD133+
CD10− THY1−
CD31/CD45 (Lind)
EpCAM
CD49f
ALDH
ErbB3 [29]
Lin− EpCAM+CD49f− Mature Luminal cells +++ +++ qRT-PCR
Lin− EpCAM+ CD49f+
ALDH+ ErbB3+
Luminal progenitors
(High CFC frequency)
++ ++
Lin− EpCAM+ CD49f+
ALDH - ErbB3+
Luminal progenitors
(Low CFC frequency)
++ ++
CD31/CD45/CD235a
(Lin)
EpCAM
CD49f
[25, 26]
Lin− EpCAM+ CD49f− Mature Luminal cells +++ +++ qRT-PCR; ICCe
(% of positive cells)55 % 71 %
Lin− EpCAM+ CD49f+ Luminal Progenitor Cells + +
28 % 2 %
Lin− EpCAM− CD49fHigh MaSC-enriched Basal cells +/− +
0.2 % 0.0 %
ALDH [27] ALDH+ Stem/progenitor cells 0 % NDf ICC; Flow cytometry
(% of positive cells)
aRT-PCR reverse transcription polymerase chain reaction
b LongSAGE long serial analysis of gene expression
c qRT-PCR quantitative Real-Time PCR
d Lin lineage
e ICC immunocytochemistry
fND not determined
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Hormone Receptor Expression in Functionally
Distinct Human Mammary Epithelial Cell
Populations
As they rarely co-localise with proliferation markers in the
normal breast [20] and are positive for cycle inhibitory factors
[38, 39], ER-expressing cells have been historically consid-
ered terminally differentiated mammary cells. ER-positive
cells are distributed through the breast luminal epithelium,
often found in close proximity to ER-negative proliferating
cells, supporting the model of an indirect response of prolif-
erating cells to oestrogen [20, 40]. Poorly developed lobules
with the least complex architecture and the highest prolifera-
tive index seem to be the sites enriched for progenitor cells
[41] as well as ER- and PR-positive cells [41, 40].
Despite the typical lack of co-localisation of ER staining
and proliferative markers, slowly-dividing cells have been
identified nonetheless among ER- and PR-positive cells in
human mammary tissue implanted in mice [42]. More recent-
ly, it has been shown that a population of dual p27/ER-
positive cells has progenitor characteristics and proliferates
in response to oestrogen stimulation [43]. The extent to which
hormone receptor-positive cells overlap with progenitor cells
remains difficult to assess in situ, however, and a number of
flow sorting-based approaches have been used to isolate breast
epithelial stem, progenitor and differentiated subpopulations
and analyse them for ER and PR expression (Table 1).
CD44High CD24Low cells have been reported as breast can-
cer stem cells [44] but normal mammary cells with this phe-
notype also have properties of stem/progenitor cells [45]. The
CD44High CD24Low phenotype within the (EpCAMHigh
CD49f+) luminal cell population from normal human breast
selects for ER-negative cells and enriches for luminal progen-
itors [46]. Interestingly although CD44+ epithelial cells from
normal breast tissue lack ER and PR [33], they express andro-
gen receptor (AR) [43].
Ginestier et al. reported that high aldehyde dehydrogenase
ALDH1 activity is associated with stem\progenitor cell prop-
erties in human mammary epithelial cells (HMECs) [47]. In
situ analysis of ALDH1 and ER expression showed that cells
expressing ALDH1 typically lack expression of ER [48], but
ER-positive cells are often adjacent to ALDH1-positive cells
[27], suggesting a close hierarchical relationship and/or a
paracrine interaction between these two cell types in vivo
and consistent with an ER-negative progenitor-like phenotype
for ALDH-positive cells.
Based on CD49f and EpCAM expression, Lim et al. de-
fined three mammary epithelial subsets, a basal MaSC-
enriched (CD49fHigh EpCAM−), a luminal progenitor
(CD49f+ EpCAM+) and a mature luminal cell (CD49f−
EpCAM+) population [25, 26]. Both ESR1 and PGR tran-
scripts were preferentially expressed in mature luminal cells
rather than luminal progenitor and MaSC-enriched fractions
[26]. Consistent with this, most of ER- and PR-positive cells
were found in the mature luminal subset, while cells of the
MaSC-enriched population did not express these receptors
[25]. As predicted from expression of c-Kit in the luminal
progenitors and ER in the mature luminal cells in cell separa-
tion experiments [26, 25], in situ analysis of c-Kit and ER [49,
50] or PR [50] demonstrated mutually exclusive staining in
the breast epithelium.
Using a larger panel of markers, four distinct mammary cell
populations, reported as bipotent CFC-enriched (EpCAM+
CD49f+ MUC1− CD133− CD10+ THY1+), luminal-
restricted CFC-enriched (EpCAM+ CD49f+ MUC1+
CD133+ CD10− THY1−), mature myoepithelial (EpCAM+
CD49f−MUC1−CD133−CD10+ THY1+) and mature luminal
(EpCAM+ CD49f− MUC1+ CD133+ CD10− THY1−) cells
Fig. 1 Properties of distinct mammary epithelial cell populations. Based
on the expression of specific cell surface markers, mammary epithelial
cells can be fractionated by FACS in basal, luminal hormone receptor-
positive and luminal hormone receptor-negative cells. The fraction
enriched in hormone receptor-positive cells contains stem and
progenitor cells at very low frequency, as assessed by transplantation
experiments and in vitro colony forming assays, respectively
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can be resolved [28, 51, 52]. Expression of ESR1 mRNA is
very heterogeneous across these populations, with the lowest
levels in the bipotent CFC-enriched fraction and the highest in
the luminal-restricted CFC-enriched fraction. Conversely,
luminal-restricted CFC-enriched cells exhibit lower PGR
mRNA levels compared to bipotent CFC-enriched cells [28].
A similar ER and PR distribution with only a partial overlap
between them across these mammary cell subsets has been
documented by another study [53], raising the possibility that
regulation of PR expression by ER may be cell-context
dependent.
Shehata et al. reported that differential ALDH activity and
ERBB3 expression can further fractionate the luminal progen-
itor (EpCAM+ CD49f+) population into three subpopulations
corresponding to undifferentiated highly clonogenic ALDH+
ERBB3+ (ALDH+) cells, and relatively differentiated less
clonogenic ALDH- ERBB3+ (ALDH-) and ALDH- ERBB3−
(ERBB3-) cells [29]. All the progenitor subpopulations
expressed lower levels of ESR1 transcript compared to mature
luminal (EpCAM+ CD49f−) cells, whilst no difference in
ESR1 expression was found among the distinct progenitor
subsets. All types of luminal progenitors displayed multi-
lineage potential when assayed using reconstitution assays,
albeit with different frequencies.
There is, therefore, a wealth of data from the human
supporting the model that mature luminal cells primarily ex-
press ER and PR and mediate the proliferative effects of steroid
hormones by paracrine signalling. However, a few studies have
indicated an enrichment of PR or ER in the progenitor popula-
tion [28, 53]. Furthermore, isolation of ER-positive cells from
normal breast tissue using a fluorescent reporter downstream of
estrogen responsive elements demonstrated that a subset of
these ER-positive cells is highly clonogenic in vitro and able
to generate progeny restricted to the luminal lineage, including
both ER-positve and ER-negative cells, in vivo [27]. A caveat
to these studies is the use of cells which have undergone a
period in culture, rather than being freshly isolated. One could
argue, however, that it is exactly this approach which allows
rare ER positive progenitors to expand and be enriched for
subsequent analysis. Nevertheless, although there is proportion
of cells with proliferative potential within the hormone
receptor-positive compartment, this cell population appears to
primarily promote proliferation in the mammary gland by para-
crine stimulation of cells lacking ER and PR.
Hormone Receptor Expression in Functionally
Distinct Mouse Mammary Epithelial Cell
Populations
Given its intracellular localization, ER is not currently an an-
tigen amenable to simple routine staining procedures for
FACS sorting and functional analysis of ER-positive cells.
As an alternative, three main strategies based on expression
of cell surface molecules have been developed for the pro-
spective isolation of ER-positive cells from the mouse mam-
mary epithelium (Table 2).
By combining CD24, a marker that allows separation of
luminal (CD24High) and basal (CD24Low) cells [54], with Sca-
1 or Prominin-1 staining, our own laboratory demonstrated
that luminal cells can be divided in two populations, CD24High
Prominin-1+/Sca-1+ and CD24High Prominin-1−/Sca-1−,
which are enriched in ER-positive and ER-negative cells, re-
spectively [32]. Most of mammary CFCs have a CD24High
Sca-1− phenotype, whilst only a small proportion of CFC is
comprised within the CD24High Sca-1+ population. Both lu-
minal populations have much lower MaSC activity than the
CD24Low basal cells, with the ER-positive population having
the lowest MRU content [30, 32]. However, the in vivo dif-
ferentiation potential of the rare luminal transplantable cells is
comparable to that of basal MaSCs [32]. Later, we demon-
strated that regardless of the ER status, expression of the ty-
rosine receptor c-Kit positively correlates with progenitor ac-
tivity in the mouse mammary epithelium [31]. Luminal ER-
negative cells express high levels of c-Kit and the few c-Kit+
cells within the luminal Sca-1+ are highly clonogenic ER-
positive cells. On the other hand, the small proportion of lu-
minal Sca-1− cells negative for c-Kit are ER-positive and lack
the ability of forming colonies in vitro. In both the ER-positive
and ER-negative luminal compartment c-Kit expression is as-
sociated with a higher number of MRUs compared to c-Kit
negative cells. Together, these results demonstrated that ER
expression is mostly dissociated fromMaSC and CFC activity
but a small population of ER-positive cells with progenitor
characteristics exist and can be purified by using a specific
set of cell surface markers.
In parallel, other studies have shown that only very few cells
in the basal MaSCs (CD29High/CD49fHigh CD24+) population
express detectable levels of ER and PR, with the great majority
of ER- and PR-positive cells being luminal (CD29Low/
CD49fLow CD24+) cells [34]. By using CD61 as additional
marker, a highly clonogenic luminal population (CD29 Low
CD24+ CD61+) can be resolved from a mature luminal cell
population (CD29Low CD24+ CD61−). Most of CD61+ luminal
cells do not express ER, whereas a high proportion of cells
within the CD61− fraction are ER-positive [35].
A third marker used for positive selection of mammary
luminal progenitors is CD49b [29]. Whereas the luminal
Sca-1− population consisted of mainly CD49b+ cells, only a
subset of Sca-1+ cells exhibited a CD49b+ phenotype. As
result, using this marker set the luminal epithelium can be
divided into a non-clonogenic ER-positive (Sca1+ CD49b−)
population along with a large ER-negative (Sca1− CD49b+)
and a small ER-positive (Sca1+ CD49b+) clonogenic cell pop-
ulation. Sca1+CD49b+ cells differed from Sca1−CD49b+ cells
for their cloning efficiency and for the morphology of the
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resulting colonies, indicating that ER-negative and ER-
positive progenitors may have distinct functional properties.
However, multiple lineage markers could be found in the col-
onies derived from both cell types. As with our own studies,
this work demonstrated that MRUs are present within both the
luminal progenitor cell populations, albeit at extremely low
frequencies, but the resulting outgrowths weremorphological-
ly normal and contain all the mammary cell lineages like those
derived from basal cells.
Lineage Tracing and Hormone Receptor Expression
A major caveat to both in vitro and in vivo proliferation/
differentiation assays on purified cell populations is that the
differentiation potential and cell fate of progenitors may be
altered outside the normal tissue environment. Fortunately,
mouse models offer powerful tools for in vivo lineage tracing
[6, 8]. To date, however, no lineage tracing study has specif-
ically addressed the developmental fate of ER-negative and
ER-positive cells but recent experiments have provided some
hints regarding the hormone receptor status of mammary pre-
cursors identified in situ.
Lineage tracing of cells expressing Notch-3, revealed that
Notch-3 marks rare and mostly quiescent cells that are recruit-
ed during mammary gland development to generate luminal
cells, both ER- negative and ER- positive [16]. Notch-3-
positive precursors are heterogeneous for ER expression
[16], and, of note, Notch-3-derived clones are composed ex-
clusively by either ER-positive or ER-negative cells [55].
Tracing experiments using the promoter of another mem-
ber of the Notch family, Notch-1, showed that in postnatal
glands Notch-1-positive precursor cells as well as their de-
scendants are luminal ER- and PR- negative cells [55]. Given
their massive expansion during pregnancy along with the abil-
ity to generate alveolar secretory cells and survive upon suc-
cessive involutions, Notch-1-labelled cells are reminiscent of
the progenitor population, known as parity-identified mam-
mary epithelial cells (PI-MECs) [56].
By using a lineage tracing strategy, Chang et al. isolated PI-
MECs from involuting glands after a single pregnancy and
found that these cells are luminal ER- and PR-negative cells
and express high levels of alveolar cell markers such as ElF5
and β-Casein [14]. In contrast to the broad differentiation
potential shown by PI-MECs in transplantation assays [56],
the lineage potential of PI-MECs in intact mammary glands is
almost entirely restricted to luminal steroid receptor-negative
alveolar cells. During pregnancy, most of the alveolar luminal
cells, which are ER-negative, are generated by PI-MECs [14]
but the few luminal ER-positive or basal cells within the de-
veloping alveoli do not seem to derive from PI-MECs. A
complementary picture has been observed in Notch-2-
lineage tracing experiments, which have recently revealed
the existence of two rare cell types, namely L (large) and S
(small) cells as descendants of Notch-2-positive precursors. In
particular, during pregnancy, a small number of L cells are
present in the luminal layer of each alveolus whilst the major-
ity of alveolar cells do not arise from Notch-2-positive pro-
genitors [15]. Such peculiar scenario warrants the evaluation
of steroid-receptor expression in L cells and in their Notch-2
expressing precursors.
Features of Hormone-Receptor-Positive Luminal
Cells
Several lines of evidence highlighted that ER marks a cell
population specialized in sensing levels of multiple systemic
hormones and converting them into local paracrine signals.
Indeed, in addition to elevated levels of ER, this cell popula-
tion exhibits high expression of PR and Prolactin receptor
(Prlr) [26, 30–32, 57], as well as of major paracrine mediators
of hormonal signalling, such as AREG [30] and RANKL
[26, 57].
Experiments in which ER-null and wild-type mammary
cells were transplanted either independently or as mixed pop-
ulations demonstrated that ER is required for mammary mor-
phogenesis by acting through a paracrine mechanism, as the
ER-null cells could contribute to outgrowths only in the pres-
ence of wild-type epithelium [58]. It still remains to be
established whether the ER-null epithelium failed to develop
because of a functional defect in the hormone-sensing cell
population or because the genetic ablation of ER resulted in
the ablation of the hormone-sensing compartment itself.
A detailed description of the various molecular pathways
activated by steroid hormones in cells expressing their cognate
receptors is beyond the scope of this review. In brief, both ER
and PR mainly localize to the nucleus where they function as
gene transcription regulators [5]. However, in addition to ge-
nomic effects, activated ER and PR can also induce more
rapid responses by initiating cytoplasmic signalling cascades
via non-transcriptional mechanisms [5].
Other than ER and PR, only a relative small number of
transcription factors, including Foxa1 [26, 29, 30], Msx2
[30], Myb [26, 30], Tbx3 [26], have been reported as specif-
ically expressed in the hormone-sensing cell compartment.
Co-expression between ER and the transcription factor
GATA-3 has been observed, but mainly in the differentiated
luminal compartment [35]. Most of these transcription factors
are functionally connected to ER [59, 60], indicating that the
ER transcriptional network is likely to be crucial in determin-
ing the fate and maintaining the identity of this cell
population.
Interestingly, the gene profile of ER-positive luminal cells,
isolated from the mammary gland of virgin mice, does not
mirror an ‘oestrogen-responsive’ gene signature, defined as
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the gene sets reported to be up-regulated by oestrogen in nor-
mal and tumour mammary cells [30]. This may due to con-
founding direct and paracrine effects when mixed cell popu-
lations are used for the determination of oestrogen-induced
genes. Alternatively, it may reflect an intrinsic stable gene
expression profile, characteristic of a largely differentiated
population, which undergoes subtle undetectable changes in
response to relative small fluctuations of hormones in resting
virgin glands.
In contrast, luminal cells lacking hormone receptors pref-
erentially express the alveolar lineage-specific transcription
factor Elf5 [26, 29, 30, 57, 61] and Lmo4 [26, 29, 30] as well
as genes for milk proteins, even in virgin mammary glands
[57, 29, 30, 32], suggesting a specific role for these cells as
precursors of alveolar secretory cells. Conversely, ER-positive
progenitors are likely to be committed along the ductal lineage
since they express higher levels of FoxA1 [26, 29, 30], which
has been demonstrated to be crucial for ductal but not lobular
mammary morphogenesis [59]. Consistent with this, analysis
of the in vivo effects of ER genetic ablation showed that ER
expression is vital for ductal development but is dispensable
for expression of milk protein genes [58].
Purely a Terminally Differentiated Population?
The molecular analysis of ER-positive and ER-negative cells
supports the model of an ER positive terminally differentiated
population which drive proliferation of ER-negative cells in a
paracrine manner. Lineage tracking suggests ER positive cells
can originate from ER negative cells but no groups have spe-
cifically tracked ER positive cells to determine whether a sub-
set has progenitor functions and can contribute to the expan-
sion of the ER-positive population itself in vivo. However,
current available data indicate that this may indeed be the case.
Transcriptomic analysis of the hormone-sensing popula-
tion in pregnancy relative to the virgin state has revealed the
induction of genes involved in cell cycle and DNA damage
repair early during pregnancy, thus unmasking a proliferative
potential in this compartment [62]. Indeed, oestrogen-
responsive elements have been found in the promoters of sev-
eral mitotic genes [63]. This is consistent with previous stud-
ies indicating that ER- and PR- positive cells proliferate pri-
marily in well-defined windows of normal mammary gland
development in vivo. Marked proliferation of hormone
receptor-positive cells in situ has been observed during puber-
ty [64] and early pregnancy [65, 24] and in vivo labelling of
proliferating cells indicated that a small subset of ER-positive
cells corresponds to a slowly dividing cell population in the
luminal compartment of mammary epithelium [66–68]. Injec-
tion of exogenous steroid hormones stimulates the prolifera-
tion of ER- and PR-positive cells [68, 69] while there is a
critical role for TGFβ signalling as a negative regulator of
ER-positive cell expansion [70]. Although signals that pro-
mote proliferation of ER-positive progenitors may be para-
crine or juxtacrine – perhaps emanating from more mature
ER-positive neighbours – the existence of a cell-autonomous
mechanism for stimulating proliferation of ER- and PR-
positive human mammary cells by steroid hormones has been
proposed by several in vitro studies [43, 71]. One confounding
factor, however, in the detection of proliferating ER-positive
cells is the rapid ER downregulation that occurs following
oestrogen stimulation [72]. A decrease in ER expression be-
fore the proliferative response may make difficult to detect
ER-positive cycling cells.
The number of ER-positive cells expressing proliferation
markers increases after menopause [73, 74]. Since ER expres-
sion is inversely correlated to circulating oestrogen levels in
mammary epithelial cells [75, 19], it is tempting to speculate
that in a low-oestrogen environment the luminal progenitor
pool may shift from an ER-negative to an ER-positive state.
Notably, hormone-deprivation significantly affects the prolif-
erative capacity of mouse mammary basal stem cells [76] and
luminal ER-negative progenitors but not of luminal ER-
positive progenitors [29]. However, it is not known whether
ER-positive progenitor cells have a similar selective prolifer-
ative advantage in human breast after menopause.
Conclusions and Perspectives
Significant advances have been made towards the definition of
a high-resolution map of hormone receptor expression in the
mammary epithelium. Almost two decades ago the analysis of
frequency, distribution and proliferation of hormone receptor-
positive cells in situ suggested a paracrine mechanism of hor-
mone action (Fig. 2), but provided limited information about
the identity and functional/lineage relationships of these cells or
the distinct molecular mechanisms.
More recently, the ability to prospectively isolate and inter-
rogate discrete mammary epithelial cell subpopulations with
features of stem, progenitor or mature cells has been crucial
for the characterization of the hormone receptor expression
pattern along the mammary differentiation hierarchy. Impor-
tantly, the identification of cell surface markers to enrich for
mammary cells expressing or lacking hormone receptors has
allowed the determination of the proliferative capacity and the
differentiation potential of these two cell subsets.
Increasing evidence shows that, although a large fraction of
hormone receptor-positive cells are mature luminal cells, a
minor proportion have properties of progenitors. However,
the relationship between the hormone receptor-positive cells
characterized as progenitors ex vivo and the rare proliferating
hormone receptor-positive cells identified in situ remains to be
elucidated. Now, the challenge is to delineate the signalling
pathways which specifically regulate the behaviour of these
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two hormone sensing cell types. A robust strategy for purify-
ing mature and progenitor hormone receptor-positive cells
will be necessary for the determination of their gene expres-
sion profiles. In addition, investigating the distribution of spe-
cific receptor isoforms, co-regulator partners and post-
translational modifications may clarify the differential cell re-
sponse to hormonal stimulation.
An important goal will be the identification of promoters
selectively active in the hormone receptor-positive progenitor
cells to enable their developmental fate in vivo to be deter-
mined through lineage-tracing experiments. Specific pro-
moters could be also used for addressing oncogenic mutations
in either differentiated or immature hormone receptor-positive
cells, in order to generate novel mouse mammary tumour
models, which may more closely resemble specific human
breast tumour subtypes and provide important insights into
their cellular origin.
Finally, it is interesting to speculate on the profound change
seen in the relationship between the majority of proliferating
cells and the majority of hormone receptor expressing cells in
the normal human breast and in breast cancer. Why do ER-
positive cells express proliferative markers in breast cancer
but not (in the majority of cells) in the normal breast? Do
mature, terminally differentiated cells ER-positive cells revert
to a progenitor-like phenotype in breast cancer? Or, is ER-
positive breast cancer the result of an uncontrolled expansion
of a rare ER-positive progenitor population? Understanding
this question will go a long way to understanding the under-
lying etiology of the most common form of the disease.
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